PURPOSE: Combination programmed cell death protein 1/cytotoxic T-cell lymphocyte-4–blockade and dual BRAF/MEK inhibition have each shown significant clinical benefit in patients with BRAFV600-mutant metastatic melanoma, leading to broad regulatory approval. Little prospective data exist to guide the choice of either initial therapy or treatment sequence in this population. This study was conducted to determine which initial treatment or treatment sequence produced the best efficacy. PATIENTS AND METHODS: In a phase III trial, patients with treatment-naive BRAFV600-mutant metastatic melanoma were randomly assigned to receive either combination nivolumab/ipilimumab (arm A) or dabrafenib/trametinib (arm B) in step 1, and at disease progression were enrolled in step 2 to receive the alternate therapy, dabrafenib/trametinib (arm C) or nivolumab/ipilimumab (arm D). The primary end point was 2-year overall survival (OS). Secondary end points were 3-year OS, objective response rate, response duration, progression-free survival, crossover feasibility, and safety. RESULTS: A total of 265 patients were enrolled, with 73 going onto step 2 (27 in arm C and 46 in arm D). The study was stopped early by the independent Data Safety Monitoring Committee because of a clinically significant end point being achieved. The 2-year OS for those starting on arm A was 71.8% (95% CI, 62.5 to 79.1) and arm B 51.5% (95% CI, 41.7 to 60.4; log-rank P = .010). Step 1 progression-free survival favored arm A ( P = .054). Objective response rates were arm A: 46.0%; arm B: 43.0%; arm C: 47.8%; and arm D: 29.6%. Median duration of response was not reached for arm A and 12.7 months for arm B ( P < .001). Crossover occurred in 52% of patients with documented disease progression. Grade ≥ 3 toxicities occurred with similar frequency between arms, and regimen toxicity profiles were as anticipated. CONCLUSION: Combination nivolumab/ipilimumab followed by BRAF and MEK inhibitor therapy, if necessary, should be the preferred treatment sequence for a large majority of patients.
Background: Patients with cancer are at increased risk of QT interval prolongation because of polypharmacy and concomitant use of QT‐prolonging medications. Drug–drug interactions (DDIs) may further increase this risk. Outpatient electrocardiogram (ECG) monitoring appears to be underused among patients receiving oral anticancer drugs (OADs). Our study objective was to evaluate the prevalence and characteristics of potential QT interval–prolonging drug–drug interactions (QT pDDIs) in patients with cancer receiving OAD therapy. Methods: A retrospective observational study was conducted using electronic health record data from 3697 patients with advanced cancer. Patients who received at least one OAD were included in the analysis. Potential QT‐related DDIs were identified through overlap prescriptions of concomitant medications associated with QT prolongation and/or Cytochrome P450‐ (CYP‐) or drug transporter‐mediated interactions during OAD exposure. Descriptive analyses were performed to characterize the prevalence and types of QT pDDIs. Results: Of the 3697 patients, 1732 (46.8%) received at least one OAD and were included in the analysis. Of these, 17.1% experienced at least one QT pDDI. Among those patients, 47.5% experienced PD‐QT pDDIs only, 21.2% experienced PK‐QT pDDIs only, and 31.3% experienced both PD‐ and PK‐QT pDDIs during OAD exposure. Concurrent PD and PK mechanisms occurred simultaneously in 30.6% of patients with QT‐pDDIs. Approximately 48% of identified QT pDDIs involved at least one OAD, most commonly pazopanib (13.5%), palbociclib (11.3%), and vandetanib (8.4%). Conclusion: QT pDDIs were common among patients with cancer receiving OADs, highlighting the importance of comprehensive DDI screening, careful medication review, and enhanced cardiac monitoring strategies in oncology practice.